Yahoo · Aug 31, 2026
Zacks Industry Outlook Highlights Amphastar Pharmaceuticals, Sandoz and Viatris
Amphastar Pharmaceuticals, Sandoz and Viatris are positioned to benefit from new launches, biosimilars and a shift toward higher-value generics.
NASDAQ · VTRS
Viatris Inc.
Healthcare · Drug Manufacturers - Specialty & Generic
$16.38
Down-$0.12 (-0.73%)
Updated Sep 11, 2026, 2:21 AM
SID Score
7.5/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 13.35B
- P/E ratio
- -3.66
- Dividend yield
- 2.93%
- 52-week range
- $10.99 – $18.39
- Volume
- 9.01M
- Avg. volume
- 9.37M
Price performance
VTRS price history
1M range · 0 trading sessions · Daily adjusted prices
VTRS does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest VTRS news
The latest Smart Investors Daily articles mentioning VTRS.
Stock researchCompany · Overview
VTRS research
Overview
Company profile and research snapshot.
Company profile
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $15.00
- Implied upside
- —
- Analysts
- 17
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 9, 2026 | Leerink Partners | Outperform | — |
| Sep 8, 2026 | Argus Research | Buy | — |
| May 19, 2026 | Barclays | Overweight | — |
| May 8, 2026 | Truist Securities | Buy | — |
| May 8, 2026 | JP Morgan | Neutral | — |
News briefing
No generated briefing is available yet.
Yahoo · Aug 29, 2026
Viatris (VTRS) Faces Fresh Generic Earnings Questions, Is The 12% Discount Enough?
Why recent generic drug earnings matter for Viatris stock Recent earnings across the generic drug industry highlighted steady demand alongside pricing and supply challenges, putting fresh attention on how Viatris (VTRS) is using new launches, product mix, and cost discipline to support its business. At a share price of US$16.34, Viatris has seen some short term pressure, with the 1 day share price return declining 3.26% and the 1 month share price return down 8.31%. However, the year to date...
Yahoo · Aug 28, 2026
Cavendish reiterates 'buy' rating on Shield Therapeutics after US deal with Viatris
Cavendish has reiterated its buy rating on Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) following the pharmaceutical company's agreement to take full commercial control of its main United States (US) product from Viatris. The broker kept its target price at 23 pence, implying potential...
Yahoo · Aug 27, 2026
3 Generic Drug Stocks to Watch Amid Improving Industry Trends
The Medical - Generic Drugs industry gains from new launches, biosimilar momentum and portfolio shifts, despite pricing pressure and supply challenges.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
